TY - JOUR
T1 - Gastrointestinal Symptoms After Resection of Esophagogastric Cancer
T2 - A Longitudinal Study on Their Incidence and Impact on Patient-Reported Outcomes
AU - van Erning, Felice N.
AU - Nieuwenhuijzen, Grard A. P.
AU - van Laarhoven, Hanneke W. M.
AU - Rosman, Camiel
AU - Gisbertz, Suzanne S.
AU - Heisterkamp, Joos
AU - Lagarde, Sjoerd M.
AU - Slingerland, Marije
AU - van den Berg, Jan-Willem
AU - Kouwenhoven, Ewout A.
AU - Verhoeven, Rob H. A.
AU - Vissers, Pauline A. J.
N1 - Funding Information: Authors FvE, GN, JWB, CR, SSG, SL, MS, JH, and PV have nothing to disclose. Author HvL: Consultant or advisory role for Amphera, AstraZeneca, Beigene, BMS, Daiichy-Sankyo, Dragonfly, Eli Lilly, MSD, Nordic Pharma, Servier. Received research funding and/or medication supply from Bayer, BMS, Celgene, Janssen, Incyte, Eli Lilly, MSD, Nordic Pharma, Philips, Roche, Servier. Received funds for speaker role from Astellas, Benecke, Daiichy-Sankyo, JAAP, Medtalks, Novartis, Travel Congress Management BV. Author EK: Consultant or advisory role Intuitive Surgical. Author RV: Grant BMS, consultant role: Daiichi Sankyo. The data collection for POCOP was funded by the Dutch cancer society (project number: UVA 2014-7000). The funder had no role in the study design, data collection and analysis, preparation of the manuscript or decision to publish. Funding Information: The authors thank the registration team of The Netherlands Comprehensive Cancer Organisation (IKNL) for the collection of data for The Netherlands Cancer Registry. Moreover, we are thankful for the POCOP data collection in all participating hospitals: Amsterdam University Medical Center, Amsterdam; Amphia, Breda; Leids University Medical Center, Leiden; Medical Spectrum Twente, Twente; St. Antonius Hospital, Utrecht; Rijnstate, Arnhem; Radboud University Medical Center, Nijmegen; Isala, Zwolle; Bovenij hospital, Amsterdam; University Medical Center Utrecht, Utrecht; Flevohospital, Almere; Elisabeth-TweeSteden hospital, Tilburg; St. Antonius, Sneek; Catharina hospital, Eindhoven; Albert Schweitzer hospital; Jeroen Bosch hospital, 's-Hertogenbosch; Martini hospital, Groningen; Maxima Medical Center, Eindhoven; Elkerliek, Helmond; SJG Weert, Weert; Bernhoven, Uden; St. Jans Gasthuis, Weert; ZorgSaam hospital, Terneuzen; Reinier de Graaf Gasthuis, Delft; Zorggroep Twente, Almelo/Hengelo; Van Weel-Bethesda hospital, Dirksland; Maastricht University Medical Center, Maastricht; Erasmus Medical Center, Rotterdam; Haga hospital, Den Haag; Spaarne Gasthuis, Haarlem; Meander Medical Center, Amersfoort; Northwest Clinics, Alkmaar; Gelre hospital, Apeldoorn; Rode Kruis hospital, Beverwijk; Ikazia hospital, Rotterdam; Albert Schweitzer hospital, Dordrecht; Antoni van Leeuwenhoek, Amsterdam; University Medical Center Groningen, Groningen; Slingeland Hospital, Doetinchem; St. Anna Zorggroep, Geldrop; Zuyderland, Sittard; Medical Center Leeuwarden; Canisius-Wilhelmina hospital, Nijmegen; Maasstad hospital, Rotterdam; Admiraal de Ruyter hospital, Goes; Bravis hospital, Roosendaal; Tjongerschans, Heerenveen; Groene Hart hospital, Gouda; Streekziekenhuis Koning Beatrix, Winterswijk; Treant Zorggroep, Stadskanaal; Laurentius hospital, Roermond; St. Jansdal, Harderwijk; Nij Smellinghe, Drachten; Alrijne hospital, Leiden; Amstelland hospital, Amstelveen; Deventer hospital, Deventer; Gelderse Vallei, Ede; Haaglanden Medical Center, Den Haag; Tergooi Medical Center, Blaricum and Hilversum; VieCuri Medical Center, Venlo. Publisher Copyright: © 2023, Society of Surgical Oncology.
PY - 2023/12
Y1 - 2023/12
N2 - Background: This study assesses the incidence of gastrointestinal symptoms in the first year after resection of esophageal or gastric cancer and its association with health-related quality of life (HRQoL), functioning, work productivity, and daily activities. Patients and Methods: Patients diagnosed with esophageal or gastric cancer between 2015 and 2021, who underwent a resection, and completed ≥ 2 questionnaires from the time intervals prior to resection and 0–3, 3–6, 6–9, and 9–12 months after resection were included. Multivariable generalized linear mixed models were used to assess changes in gastrointestinal symptoms over time and the impact of the number of gastrointestinal symptoms on HRQoL, functioning, work productivity, and daily activities for patients who underwent an esophagectomy or gastrectomy separately. Results: The study population consisted of 961 (78.8%) and 259 (21.2%) patients who underwent an esophagectomy and gastrectomy, respectively. For both groups, the majority of gastrointestinal symptoms changed significantly over time. Most clinically relevant differences were observed 0–3 after resection compared with prior to resection and included increased diarrhea, appetite loss, and eating restrictions, and specifically after esophagectomy dry mouth, trouble with coughing, and trouble talking. At 9–12 after resection one or more severe gastrointestinal symptoms were reported by 38.9% after esophagectomy and 33.7% after gastrectomy. A higher number of gastrointestinal symptoms was associated with poorer functioning, lower HRQoL, higher impairment in daily activities, and lower work productivity. Conclusions: This study shows that gastrointestinal symptoms are frequently observed and burdensome after esophagectomy or gastrectomy, highlighting the importance to address these sequelae for high quality survivorship.
AB - Background: This study assesses the incidence of gastrointestinal symptoms in the first year after resection of esophageal or gastric cancer and its association with health-related quality of life (HRQoL), functioning, work productivity, and daily activities. Patients and Methods: Patients diagnosed with esophageal or gastric cancer between 2015 and 2021, who underwent a resection, and completed ≥ 2 questionnaires from the time intervals prior to resection and 0–3, 3–6, 6–9, and 9–12 months after resection were included. Multivariable generalized linear mixed models were used to assess changes in gastrointestinal symptoms over time and the impact of the number of gastrointestinal symptoms on HRQoL, functioning, work productivity, and daily activities for patients who underwent an esophagectomy or gastrectomy separately. Results: The study population consisted of 961 (78.8%) and 259 (21.2%) patients who underwent an esophagectomy and gastrectomy, respectively. For both groups, the majority of gastrointestinal symptoms changed significantly over time. Most clinically relevant differences were observed 0–3 after resection compared with prior to resection and included increased diarrhea, appetite loss, and eating restrictions, and specifically after esophagectomy dry mouth, trouble with coughing, and trouble talking. At 9–12 after resection one or more severe gastrointestinal symptoms were reported by 38.9% after esophagectomy and 33.7% after gastrectomy. A higher number of gastrointestinal symptoms was associated with poorer functioning, lower HRQoL, higher impairment in daily activities, and lower work productivity. Conclusions: This study shows that gastrointestinal symptoms are frequently observed and burdensome after esophagectomy or gastrectomy, highlighting the importance to address these sequelae for high quality survivorship.
KW - Esophagectomy
KW - Esophagogastric cancer
KW - Gastrectomy
KW - Gastrointestinal symptoms
KW - Longitudinal study
KW - Patient-reported outcomes
UR - http://www.scopus.com/inward/record.url?scp=85165677112&partnerID=8YFLogxK
U2 - https://doi.org/10.1245/s10434-023-13952-z
DO - https://doi.org/10.1245/s10434-023-13952-z
M3 - Article
C2 - 37523120
SN - 1068-9265
VL - 30
SP - 8203
EP - 8215
JO - Annals of surgical oncology
JF - Annals of surgical oncology
IS - 13
ER -